Viking Therapeutics (VKTX) announced the initiation of the Vanquish Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200%
- Viking Therapeutics management to meet with B. Riley
- Viking Therapeutics Holds Annual Stockholders Meeting
- Viking Therapeutics put volume heavy and directionally bearish
- ARMOUR, BioCryst, Viking, Builders, Hims: Trending by Analysts